LAVA Therapeutics N.V.
NASDAQ: LVTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen Allen Hurly
- Employees
- 34
- Headquarters
- Utrecht, Netherlands
- IPO year
- 2021
- Market cap
- $45.8M
- Website
- https://www.lavatherapeutics.com
Loading LVTX…
Loading profile data…Frequently asked questions about LVTX
What does LAVA Therapeutics N.V. (LVTX) do?
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilit...
Where does LVTX trade?
LAVA Therapeutics N.V. (LVTX) trades on the NASDAQ Global Select.
What sector is LVTX in?
LAVA Therapeutics N.V. (LVTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of LAVA Therapeutics N.V.?
Stephen Allen Hurly is the chief executive officer of LAVA Therapeutics N.V. (LVTX).
Where is LAVA Therapeutics N.V. headquartered?
LAVA Therapeutics N.V. is headquartered in Netherlands.
Does LVTX pay a dividend?
LAVA Therapeutics N.V. (LVTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LVTX go public?
LAVA Therapeutics N.V. (LVTX) completed its initial public offering in 2021.